chronic hepatitis B
Conditions
Interventions
Horizontal and vertical groups:None
Sponsors
Children’s Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
2 Years to 16 Years
Inclusion criteria
Inclusion criteria: Entecavir group:Children with chronic type B hepatitis were included retrospectively. According to the therapeutic effect in 48 weeks, the responders defined as the lack of serum HBeAg, low or undetectable HBV DNA levels ( 10^7 IU/ml, alanine aminotransferase ( ALT ) consistently within the normal range . Imunne active ( IA ) phase, recurrently HBeAg-positive chronic hepatitis B, is characterised by the presence of serum HBeAg, HBV DNA >10^4IU/ml and elevated ALT. Combined response ( CR ) were defined as the lack of serum HBeAg, low or undetectable HBV DNA levels ( <2000IU/ml ), and ALT normalization after receiving antiviral therapy. Vertical group: Children with HBsAg or HBV DNA positive at least 6 months were treated with entecavir and followed up for at least 48 weeks in our hospital
Exclusion criteria
Exclusion criteria: Patients with decompensated cirrhosis, hepatocellular carcinoma, liver failure, liver transplantation, chronic immunosuppressive status, other liver diseases (such as autoimmune hepatitis, drug-induced liver injury or Wilson's disease) , or infection with other hepatophilic viruses (such as Hepatitis C virus)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of CCR5+CD8+T cells; | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of IL2+CCR5+CD8+T cells;Frequency of TNFa+CCR5+CD8+T cells;Frequency of IFN-?+CCR5+CD8+T cells;Frequency of PD1+CCR5+CD8+T cells;Frequency of TIM3+CCR5+CD8+T cells;Frequency of CTLA4+CCR5+CD8+T cells;Frequency of CD69+CCR5+CD8+T cells;Frequency of CD38+CCR5+CD8+T cells;Frequency of CD25+CCR5+CD8+T cells; | — |
Countries
China
Contacts
Public ContactHongmei Xu
Children’s Hospital of Chongqing Medical University
Outcome results
None listed